The clinical response to TKIs for patients with NSCLC is limited by primary and secondary resistance to the therapy and classic biomarkers cannot be used to predict which patients may develop such ...
A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung ...
To see if this affects the SHH pathway, they introduced the genes into cells lacking LRP2 function. "We were able to see that they significantly boost the Sonic Hedgehog signaling pathway," says ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results